Summary
Zogenix Inc (Zogenix) is a provider of therapies for central nervous system disorders. The company’s product portfolio comprises Zohydro ER, Sumavel DosePro and undisclosed dosepro CNS product candidate. Its pipeline products include Relday and ZX008. Zogenix’s Sumavel DosePro is a prefilled needle-free delivery system that treats people with acute migraine or cluster headaches. The company develops pipeline products for dravet syndrome, and rare and catastrophic form of epilepsy beginning in infancy. It also offers education materials on therapeutic products for patients and physicians. Zogenix is headquartered in Emeryville, California, the US.
Zogenix Inc (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Zogenix Inc, Medical Devices Deals, 2011 to YTD 2017 10
Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Zogenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Cowen Healthcare Royalty Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix 12
Partnerships 14
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 14
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 15
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 16
Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro 17
Licensing Agreements 18
Zogenix International Amends Licensing Agreement with University of Antwerp and University of Leuven 18
Zogenix Amends Licensing Agreement with Daravita 19
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 20
Zogenix Amends Agreement with Elan Pharma 21
Equity Offering 22
Zogenix Raises USD289 Million in Public Offering of Shares 22
Zogenix Raises USD98.3 Million in Public Offering of Shares 24
Zogenix Raised USD10.8 Million in Public Offering Of Shares 26
Zogenix Completes Public Offering Of Shares For US$69 Million 27
Zogenix Completes Public Offering Of Units For US$70 Million 29
Zogenix Completes Public Offering Of Common Stock For US$61.4 Million 30
Zogenix Completes Private Placement Of Common Stock For US$1.5 Million 32
Asset Transactions 33
Pernix Acquires Zohydro ER Business from Zogenix 33
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 35
Acquisition 36
Zogenix Acquires Brabant Pharma for USD130 Million 36
Zogenix Inc - Key Competitors 37
Zogenix Inc - Key Employees 38
Zogenix Inc - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 08, 2017: Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results 40
May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 42
Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 43
Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results 45
Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results 47
May 10, 2016: Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results 49
Mar 10, 2016: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results 50
Corporate Communications 52
Jan 05, 2017: Zogenix Announces CFO Transition 52
Product News 53
04/21/2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 53
Product Approvals 54
Mar 01, 2017: Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome 54
Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 55
Clinical Trials 56
Feb 13, 2017: Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome 56
Dec 05, 2016: Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome 57
Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 59
Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome 61
May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 62
Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List Of Tables
List of Tables
Zogenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zogenix Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Zogenix Inc, Medical Devices Deals, 2011 to YTD 2017 10
Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cowen Healthcare Royalty Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix 12
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 14
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 15
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 16
Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro 17
Zogenix International Amends Licensing Agreement with University of Antwerp and University of Leuven 18
Zogenix Amends Licensing Agreement with Daravita 19
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 20
Zogenix Amends Agreement with Elan Pharma 21
Zogenix Raises USD289 Million in Public Offering of Shares 22
Zogenix Raises USD98.3 Million in Public Offering of Shares 24
Zogenix Raised USD10.8 Million in Public Offering Of Shares 26
Zogenix Completes Public Offering Of Shares For US$69 Million 27
Zogenix Completes Public Offering Of Units For US$70 Million 29
Zogenix Completes Public Offering Of Common Stock For US$61.4 Million 30
Zogenix Completes Private Placement Of Common Stock For US$1.5 Million 32
Pernix Acquires Zohydro ER Business from Zogenix 33
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 35
Zogenix Acquires Brabant Pharma for USD130 Million 36
Zogenix Inc, Key Competitors 37
Zogenix Inc, Key Employees 38
Zogenix Inc, Other Locations 39
Zogenix Inc, Subsidiaries 39
List Of Figures
List of Figures
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Zogenix Inc, Medical Devices Deals, 2011 to YTD 2017 10
